Crick
HomeTrialsGenesDrugs23andMeGraphBlogContact
  • Home
  • Trials
  • Genes
  • Drugs
  • 23andMe
  • Graph
  • Blog
  • Contact
Crick

An open-source clinical intelligence platform. Explore clinical trials, gene networks, and molecular structures using public data sources.

Data Sources

  • ClinicalTrials.gov
  • OpenTargets
  • ClinVar
  • PubChem

Links

  • Contact
  • Privacy

© 2026 Crick. All rights reserved.

Crick is for educational purposes only. Not medical advice.

Results for “Dual-target CAR-T Cells”

Filters

Phase
Early Phase 1
Phase 1
Phase 2
Phase 3
Phase 4
Status
Recruiting
Active, Not Recruiting
Not Yet Recruiting
Completed
Enrolling by Invitation

Showing 20 of 0 results

Early research (Phase 1)Looking for participantsNCT05388695
What this trial is testing

To Observe the Dual-target Chimeric Antigen Receptor T Cells in the Treatment of B Cell Hematologic Tumors

Who this might be right for
19 and 22+ B Cell Hematologic Tumors19 and 20+ B Cell Hematologic Tumors
Hebei Senlang Biotechnology Inc., Ltd. 100
Testing effectiveness (Phase 2)Not Yet RecruitingNCT07162571
What this trial is testing

This is a Phase I/II Interventional, Open-label Treatment Study Designed to Evaluate the Safety and Efficacy of Anti CD 19/22 CAR- T Cells Immunotherapy for Adults With Relapsed or Refractory Acute Lymphoblastic Leukemia/Lymphoma.

Who this might be right for
Acute Lymphobkastic LeukemiaB Cell Lymphoma
Minsk Scientific-Practical Center for Surgery, Transplantation and Hematology 17
Large-scale testing (Phase 3)Not Yet RecruitingNCT07735637
What this trial is testing

A Phase III, Multicentre Study to Evaluate Consolidation Treatment With AZD0120 Compared With ASCT, in Participants With Newly Diagnosed Multiple Myeloma Who Are Transplant Eligible (DURGA-6).

Who this might be right for
Newly Diagnosed Multiple Myeloma (NDMM)
AstraZeneca 750
Testing effectiveness (Phase 2)UnknownNCT03398967
What this trial is testing

A Feasibility and Safety Study of Universal Dual Specificity CD19 and CD20 or CD22 CAR-T Cell Immunotherapy for Relapsed or Refractory Leukemia and Lymphoma

Who this might be right for
B Cell LeukemiaB Cell Lymphoma
Chinese PLA General Hospital 80
Testing effectiveness (Phase 2)Looking for participantsNCT05826535
What this trial is testing

Study of Rondecabtagene Autoleucel in Aggressive Large B-Cell Lymphoma

Who this might be right for
Relapsed Non-Hodgkin LymphomaRefractory Non-Hodgkin LymphomaNon-Hodgkin Lymphoma+1 more
Lyell Immunopharma, Inc. 270
Early research (Phase 1)Not Yet RecruitingNCT07024147
What this trial is testing

JWCAR239 in Patients With B Cell Non-Hodgkin Lymphoma

Who this might be right for
B-Cell Non-Hodgkin LymphomaLarge B Cell Diffuse LymphomaFollicular Lymphoma+2 more
Peking University Cancer Hospital & Institute 20
Testing effectiveness (Phase 2)Looking for participantsNCT06735495
What this trial is testing

CD19 & CD22 Bispecific CAR T Cells in the Treatment of Relapsed/Refractory B Cell Hematologic Tumors

Who this might be right for
B-Cell Lymphoblastic Leukemia/Lymphoma
Union Hospital, Tongji Medical College, Huazhong University of Science and Technology 80
Early research (Phase 1)Not Yet RecruitingNCT07763938
What this trial is testing

CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

Who this might be right for
Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University 80
Early research (Phase 1)Looking for participantsNCT07361094
What this trial is testing

Autologous CD19/BCMA Dual-Target CAR-T for Relapsed/Refractory Autoimmune Diseases

Who this might be right for
Relapsed/Refractory Systemic Lupus ErythematosusRelapsed/Refractory Systemic SclerosisRelapsed/Refractory Idiopathic Inflammatory Myopathies+3 more
Beijing Boren Hospital 12
Very early researchNot Yet RecruitingNCT07586709
What this trial is testing

In Vivo BCMA/GPRC5D Tandem Dual CAR-T Therapy for Relapsed/Refractory Plasma Cell Neoplasms

Who this might be right for
Plasma Cell Neoplasms
Liping Dou 18
Very early researchLooking for participantsNCT07519187
What this trial is testing

CAR 70-BCMA CAR-T Cells for the Treatment of Relapsed or Refractory Plasma Cell Neoplasms

Who this might be right for
Relapsed or Refractory Plasma Cell Neoplasms
The General Hospital of Western Theater Command 20
Testing effectiveness (Phase 2)Looking for participantsNCT07066995
What this trial is testing

Mesothelin and Claudin 18.2 Dual-Target CAR-T Therapy in Advanced Pancreatic Cancer

Who this might be right for
Pancreatic CancerPancreatic CarcinomaPancreatic Cancer Non-resectable+1 more
Essen Biotech 60
Early research (Phase 1)Looking for participantsNCT06084286
What this trial is testing

Dual-targeting CLDN18.2 and PD-L1 CAR-T for Patients with CLDN18.2-positive Advanced Solid Tumors

Who this might be right for
Advanced Solid Tumor
Sichuan University 29
Very early researchUnknownNCT04412889
What this trial is testing

BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory MM

Who this might be right for
Multiple Myeloma
Hebei Yanda Ludaopei Hospital 18
Very early researchUnknownNCT04182581
What this trial is testing

BCMA/CD19 Dual-Target CAR-T Cell Immunotherapy for Relapsed or Refractory Multiple Myeloma

Who this might be right for
Multiple Myeloma
Xijing Hospital 18
Very early researchUnknownNCT04236011
What this trial is testing

BCMA and CD19 Targeted Fast Dual CAR-T for BCMA+ Refractory/Relapsed Multiple Myeloma

Who this might be right for
Multiple Myeloma
Shanghai Changzheng Hospital 15
Very early researchLooking for participantsNCT05858684
What this trial is testing

Dual Target CAR-T Cell Treatment for Refractory Systemic Lupus Erythematosus (SLE) Patients

Who this might be right for
CAR-T Cell Therapy
RenJi Hospital 18
Early research (Phase 1)Looking for participantsNCT07002112
What this trial is testing

The CD19/CD20 Dual-Target in Vivo CAR-T Lentiviral Product in the Treatment of Relapsed/Refractory B-cell Malignancies

Who this might be right for
Relapsed/Refractory B-cell Malignancies
The First Affiliated Hospital with Nanjing Medical University 30
Testing effectiveness (Phase 2)Looking for participantsNCT07575971
What this trial is testing

Exploratory Study of CD22/CD19 Dual-Target CAR-T Cell Therapy as Consolidation Treatment After First Remission in High-Risk B-Cell Acute Lymphoblastic Leukemia

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Liping Dou 30
Early research (Phase 1)Looking for participantsNCT07838714
What this trial is testing

Dual-Targeted Umbilical Cord Blood CAR-T Cells Against CD19 and CD22 for the Treatment of Relapsed or Refractory Acute B-Cell Lymphoblastic Leukemia

Who this might be right for
B-cell Acute Lymphoblastic Leukemia
Ruijin Hospital 18
Next Page